Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
Launched by CHINA MEDICAL UNIVERSITY HOSPITAL · May 18, 2006
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
In the study, 20 schizophrenic patients are recruited into the 6-week trial and randomly assigned into the two groups (1 g/d and 2 g/d) with a double-blind manner. Clinical manifestation (Positive and Negative Syndrome Scale; Scale for the Assessment of Negative Symptoms), side effects and quality of life are evaluated every two weeks during the trial. The efficacies of two groups are compared, and the characteristics of better responders are analyzed.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Fulfill the criteria of schizophrenia according to the Diagnostic and Statistic Manual, fourth edition (DSM-IV).
- • Free from antipsychotics for at least 7 days before enrollment.
- • Agree to participate in the study and provide informed consent
- Exclusion Criteria:
- • Meet DSM-IV criteria of major mood disorder, current substance dependence or mental retardation
- • History of epilepsy, head trauma or CNS diseases
- • Major, untreated medical diseases
- • Pregnancy or lactation
- • Receiving psychotropic agents or depot within three months prior to study entry
About China Medical University Hospital
China Medical University Hospital is a leading healthcare institution dedicated to advancing medical research and enhancing patient care through innovative clinical trials. Affiliated with China Medical University, the hospital is renowned for its comprehensive approach to medical education and research, fostering collaboration between healthcare professionals and academic experts. With state-of-the-art facilities and a commitment to ethical standards, the hospital conducts rigorous clinical trials aimed at improving treatment outcomes across various medical disciplines, contributing significantly to both local and global healthcare advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taichung, , Taiwan
Patients applied
Trial Officials
Hsien-yuan Lane, MD,PhD
Principal Investigator
Dept. of Psychiatry, China Medical University Hospital, Taichung, Taiwan
Guochuan E. Tsai, MD,PhD
Study Director
Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, California
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials